...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan
【24h】

Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan

机译：氨氯地平/缬沙坦或氨氯地平/缬沙坦/氢氯噻嗪单药联用对巴基斯坦高血压患者的实际疗效，安全性和耐受性

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia. Here, we present data from Pakistan. This was a 26-week observational, multicenter, prospective, open-label study. At week 26, change from baseline in mean sitting systolic (msSBP) and diastolic blood pressure (msDBP) and the proportion of patients achieving BP goal (SBP/DBP A total of 500 patients with hypertension (mean age of 48 years) were prescribed Aml/Val (n = 471, 94%) or Aml/Val/HCTZ (n = 29, 6%); 439 (87.8%) patients completed the study. At week 26, the mean BP decreased from 153.4/91.1 mmHg at baseline to 128.9/78.4 mmHg in the Aml/Val cohort (?24.5/?12.7 mmHg; p p Aml/Val with or without HCTZ in a SPC was effective and well-tolerated for BP reduction in this cohort of patients with hypertension from Pakistan.
机译：EXCITE（氨氯地平和缬沙坦在高血压方面的临床经验）评估了氨氯地平/缬沙坦（Aml / Val）和氨氯地平/缬沙坦/氢氯噻嗪（Aml / Val /的单药组合）的现实生活有效性，安全性和耐受性来自中东和亚洲13个国家/地区的高血压患者的HCTZ）。在这里，我们提供了来自巴基斯坦的数据。这是一项为期26周的观察性，多中心，前瞻性开放标签研究。在第26周时，平均坐位收缩压（msSBP）和舒张压（msDBP）以及达到BP目标的患者比例（SBP / DBP）相对于基线的变化规定了500例高血压患者（平均年龄48岁） / Val（n = 471，94％）或Aml / Val / HCTZ（n = 29，6％）; 439（87.8％）名患者完成了研究;在第26周时，平均BP从基线的153.4 / 91.1 mmHg降低在Aml / Val队列中达到128.9 / 78.4 mmHg（？24.5 /？12.7 mmHg;在SPC中有HCTZ或无HCTZ的pp Aml / Val对巴基斯坦的这一队列高血压患者均有效且耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号